Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:50 UTC |
---|
Update Date | 2022-03-07 02:51:42 UTC |
---|
HMDB ID | HMDB0014671 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Erlotinib |
---|
Description | Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. Similar to gefitinib, erlotinib specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase. It binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. Erlotinib has recently been shown to be a potent inhibitor of JAK2V617F activity. JAK2V617F is a mutant of tyrosine kinase JAK2, is found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. The study suggests that erlotinib may be used for treatment of JAK2V617F-positive PV and other myeloproliferative disorders. |
---|
Structure | COCCOC1=C(OCCOC)C=C2C(NC3=CC=CC(=C3)C#C)=NC=NC2=C1 InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25) |
---|
Synonyms | Value | Source |
---|
[6,7-Bis(2-methoxy-ethoxy)quinazoline-4-yl]-(3-ethynylphenyl)amine | ChEBI | [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine | ChEBI | Erlotinibum | ChEBI | OSI-774 | HMDB | 11C Erlotinib | HMDB | HCL, Erlotinib | HMDB | Hydrochloride, erlotinib | HMDB | N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine | HMDB | OSI 774 | HMDB | Erlotinib hydrochloride | HMDB | 11C-Erlotinib | HMDB | Tarceva | HMDB | Erlotinib HCL | HMDB |
|
---|
Chemical Formula | C22H23N3O4 |
---|
Average Molecular Weight | 393.4357 |
---|
Monoisotopic Molecular Weight | 393.168856239 |
---|
IUPAC Name | N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine |
---|
Traditional Name | erlotinib |
---|
CAS Registry Number | 183321-74-6 |
---|
SMILES | COCCOC1=C(OCCOC)C=C2C(NC3=CC=CC(=C3)C#C)=NC=NC2=C1 |
---|
InChI Identifier | InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25) |
---|
InChI Key | AAKJLRGGTJKAMG-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Diazanaphthalenes |
---|
Sub Class | Benzodiazines |
---|
Direct Parent | Quinazolinamines |
---|
Alternative Parents | |
---|
Substituents | - Quinazolinamine
- Aniline or substituted anilines
- Alkyl aryl ether
- Aminopyrimidine
- Monocyclic benzene moiety
- Pyrimidine
- Benzenoid
- Imidolactam
- Heteroaromatic compound
- Dialkyl ether
- Ether
- Acetylide
- Secondary amine
- Azacycle
- Organonitrogen compound
- Amine
- Organic nitrogen compound
- Organooxygen compound
- Organic oxygen compound
- Hydrocarbon derivative
- Organopnictogen compound
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.0089 g/L | Not Available | LogP | 2.7 | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Erlotinib,1TMS,isomer #1 | C#CC1=CC=CC(N(C2=NC=NC3=CC(OCCOC)=C(OCCOC)C=C23)[Si](C)(C)C)=C1 | 3174.5 | Semi standard non polar | 33892256 | Erlotinib,1TMS,isomer #1 | C#CC1=CC=CC(N(C2=NC=NC3=CC(OCCOC)=C(OCCOC)C=C23)[Si](C)(C)C)=C1 | 3168.7 | Standard non polar | 33892256 | Erlotinib,1TMS,isomer #1 | C#CC1=CC=CC(N(C2=NC=NC3=CC(OCCOC)=C(OCCOC)C=C23)[Si](C)(C)C)=C1 | 4627.6 | Standard polar | 33892256 | Erlotinib,1TBDMS,isomer #1 | C#CC1=CC=CC(N(C2=NC=NC3=CC(OCCOC)=C(OCCOC)C=C23)[Si](C)(C)C(C)(C)C)=C1 | 3375.0 | Semi standard non polar | 33892256 | Erlotinib,1TBDMS,isomer #1 | C#CC1=CC=CC(N(C2=NC=NC3=CC(OCCOC)=C(OCCOC)C=C23)[Si](C)(C)C(C)(C)C)=C1 | 3338.4 | Standard non polar | 33892256 | Erlotinib,1TBDMS,isomer #1 | C#CC1=CC=CC(N(C2=NC=NC3=CC(OCCOC)=C(OCCOC)C=C23)[Si](C)(C)C(C)(C)C)=C1 | 4639.6 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Erlotinib GC-MS (Non-derivatized) - 70eV, Positive | splash10-002k-2129000000-90a20b25b74b231ffec1 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Erlotinib GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Erlotinib GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Erlotinib 10V, Positive-QTOF | splash10-0006-0009000000-0faffd4c59a79313872f | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Erlotinib 20V, Positive-QTOF | splash10-0a4l-4019000000-3b47513e20a5bfacb8f4 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Erlotinib 40V, Positive-QTOF | splash10-07fr-3092000000-09a2b2602ea3efd921bc | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Erlotinib 10V, Negative-QTOF | splash10-000x-0009000000-0e3a84b624af3648dfc4 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Erlotinib 20V, Negative-QTOF | splash10-0089-0049000000-7d705f21b90db0f6f3ca | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Erlotinib 40V, Negative-QTOF | splash10-00di-1192000000-6d6a8f8831beb774d61c | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Erlotinib 10V, Negative-QTOF | splash10-0f7o-0019000000-98c0248bef3527a16545 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Erlotinib 20V, Negative-QTOF | splash10-0fkc-0095000000-b346f0645c009b0dbd23 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Erlotinib 40V, Negative-QTOF | splash10-0uk9-2098000000-c15ff6cb37269237da44 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Erlotinib 10V, Positive-QTOF | splash10-0006-0009000000-cab9b4eadff55f06446d | 2021-09-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Erlotinib 20V, Positive-QTOF | splash10-01ox-0009000000-576d45602f85d8bf2186 | 2021-09-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Erlotinib 40V, Positive-QTOF | splash10-004i-1079000000-e0507c536b38d89e26b1 | 2021-09-25 | Wishart Lab | View Spectrum |
|
---|
General References | - Blum G, Gazit A, Levitzki A: Substrate competitive inhibitors of IGF-1 receptor kinase. Biochemistry. 2000 Dec 26;39(51):15705-12. [PubMed:11123895 ]
- Raymond E, Faivre S, Armand JP: Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs. 2000;60 Suppl 1:15-23; discussion 41-2. [PubMed:11129168 ]
- Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE, Nicholson RI: Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer. 2004 Dec;11(4):793-814. [PubMed:15613453 ]
- Dudek AZ, Kmak KL, Koopmeiners J, Keshtgarpour M: Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Lung Cancer. 2006 Jan;51(1):89-96. Epub 2005 Nov 14. [PubMed:16290256 ]
- Li Z, Xu M, Xing S, Ho WT, Ishii T, Li Q, Fu X, Zhao ZJ: Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem. 2007 Feb 9;282(6):3428-32. Epub 2006 Dec 18. [PubMed:17178722 ]
- Lansiaux A, Bailly C: [Perspectives on the oncologist pharmacopoeia]. Bull Cancer. 2003 Jan;90(1):25-30. [PubMed:12609801 ]
|
---|